E. Campo, S. H. Swerdlow, and N. L. Harris, WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5051, 2008.

S. H. Swerdlow, E. Campo, and S. A. Pileri, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-90, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

J. Ferlay, E. Steliarova-foucher, and J. Lortet-tieulent, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, Eur J Cancer, vol.49, pp.1374-403, 2013.

J. Ferlay, I. Soerjomataram, and R. Dikshit, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBO-CAN 2012, Int J Cancer, vol.136, pp.359-86, 2015.

A. Smith, S. Crouch, and S. Lax, Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network, Br J Cancer, vol.112, pp.1575-84, 2015.

B. Coiffier, E. Lepage, and J. Briere, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, vol.346, pp.235-277, 2002.

A. Monnereau, X. Troussard, and A. Belot, French Network of Cancer Registries (FRANCIM)Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France, Int J Cancer, vol.132, pp.2378-87, 2013.

N. Howlader, L. M. Morton, and E. J. Feuer, Contributions of subtypes of non-Hodgkin lymphoma to mortality trends, Cancer Epidemiol Biomark Prev, vol.25, pp.174-183, 2016.

E. Desandes, B. Lacour, and A. Belot, Cancer incidence and survival in adolescents and young adults in France, Pediatr Hematol Oncol, vol.30, pp.291-306, 2000.
URL : https://hal.archives-ouvertes.fr/hal-02168116

M. Dandoit, M. Mounier, and J. Guy, The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry, Leuk Lymphoma, vol.56, pp.1050-1057, 2015.

L. Guyader-peyrou, S. Belot, A. Maynadié, and M. , Cancer incidence in France over the 1980-2012 period: hematological malignancies, Rev Epidemiol Sante Publique, vol.64, pp.103-115, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580

J. M. Goldman and J. V. Melo, Chronic myeloid leukemia: advances in biology and new approaches to treatment, N Engl J Med, vol.349, pp.1451-64, 2003.

S. K. Kumar, S. V. Rajkumar, and A. Dispenzieri, Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, pp.2516-2536, 2008.

M. C. Palanca-wessels and O. W. Press, Advances in the treatment of hematologic malignancies using immunoconjugates, Blood, vol.123, pp.2293-301, 2014.

A. Hamilton, P. Gallipoli, and E. Nicholson, Targeted therapy in haematological malignancies, J Pathol, vol.220, pp.404-422, 2010.

G. K. Gifford, A. J. Gill, and W. S. Stevenson, Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists, Pathology, vol.48, pp.5-16, 2016.

T. Seiler, G. Hutter, and M. Dreyling, The emerging role of PI3K inhibitors in the treatment of hematological malignancies: preclinical data and clinical progress to date, Drugs, vol.76, pp.639-685, 2016.

A. Piggin, E. Bayly, and C. S. Tam, Novel agents versus chemotherapy as frontline treatment of CLL, Leuk Lymphoma, vol.58, pp.1320-1324, 2017.

K. Dunleavy, M. Roschewski, and W. H. Wilson, Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype, Clin Cancer Res, vol.20, pp.5182-93, 2014.

S. Puvvada, S. Kendrick, and L. Rimsza, Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma, Cancer Genet, vol.206, pp.257-65, 2013.

N. Freemantle, L. Marston, and K. Walters, Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research, BMJ, vol.347, p.6409, 2013.

W. B. Al-refaie, S. M. Vickers, and W. Zhong, Cancer trials versus the real world in the United States, Ann Surg, vol.254, pp.438-480, 2011.

K. Kwiatkowski, K. Coe, and J. C. Bailar, Inclusion of minorities and women in cancer clinical trials, a decade later: have we improved?, Cancer, vol.119, pp.2956-63, 2013.

L. T. Penberthy, B. A. Dahman, and V. I. Petkov, Effort required in eligibility screening for clinical trials, J Oncol Pract, vol.8, pp.365-70, 2012.

A. Ajrouche, C. Estellat, and Y. De-rycke, Evaluation of algorithms to identify incident cancer cases by using French health administrative databases, Pharmacoepidemiol Drug Saf, vol.26, pp.935-979, 2017.

G. Moulis, J. Germain, and D. Adoue, Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database, Eur J Intern Med, vol.32, pp.21-23, 2016.

G. Moulis, A. Palmaro, and J. L. Montastruc, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, vol.124, pp.3308-3323, 2014.

A. Palmaro, M. Gauthier, and C. Conte, Identifying multiple myeloma patients using data from the French health insurance databases: validation using a cancer registry, Medicine (Baltimore), vol.96, p.6189, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01907563

A. Palmaro, M. Gauthier, and F. Despas, Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients, Pharmacoepidemiol Drug Saf, vol.26, pp.1492-1501, 2017.

J. J. Fenton, T. Onega, and W. Zhu, Validation of a medicare claims-based algorithm for identifying breast cancers detected at screening mammography, Med Care, vol.54, pp.15-22, 2016.

P. Avillach, P. M. Coloma, and R. Gini, EU-ADR consortiumHarmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project, J Am Med Inform Assoc, vol.20, pp.184-92, 2013.

R. M. Carnahan and K. G. Moores, Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.82-91, 2012.

C. Quantin, E. Benzenine, and M. Hägi, Estimation of national colorectalcancer incidence using claims databases, J Cancer Epidemiol, vol.2012, p.298369, 2012.

O. Ganry, A. Taleb, and J. Peng, Evaluation of an algorithm to identify incident breast cancer cases using DRGs data, Eur J Cancer Prev, vol.12, pp.295-304, 2003.

C. M. Couris, A. Seigneurin, and S. Bouzbid, French claims data as a source of information to describe cancer incidence: predictive values of two identification methods of incident prostate cancers, J Med Syst, vol.30, pp.459-63, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00427927

L. Remontet, N. Mitton, and C. M. Couris, Is it possible to estimate the incidence of breast cancer from medico-administrative databases?, Eur J Epidemiol, vol.23, pp.681-689, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00338952

Z. Hafdi-nejjari, C. M. Couris, and A. M. Schott, Role of hospital claims databases from care units for estimating thyroid cancer incidence in the Rhône-Alpes region of France, Rev Dépidémiologie Santé Publique, vol.54, pp.391-399, 2006.

N. Carré, Z. Uhry, and M. Velten, Predictive value and sensibility of hospital discharge system (PMSI) compared to cancer registries for thyroïd cancer, Rev Dépidémiologie Santé Publique, vol.54, pp.367-76, 1999.

G. Coureau, I. Baldi, and M. Saves, Performance evaluation of hospital claims database for the identification of incident central nervous system tumors compared with a cancer registry, Rev DÉpidémiologie Santé Publique, vol.60, pp.295-304, 2004.

S. Setoguchi, D. H. Solomon, and R. J. Glynn, Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data, Cancer Causes Control, vol.18, pp.561-570, 2007.

, Registre des cancers du Tarn (registre qualifié 2010-2013) /Portail Epidemiologie -France j Health Databases, 2017.

. Accessed, , 2017.

R. A. Herman, B. Gilchrist, and B. K. Link, A systematic review of validated methods for identifying lymphoma using administrative data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.203-215, 2012.

M. Hallek, B. D. Cheson, and D. Catovsky, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, pp.5446-56, 2008.

R. Willemze, E. Hodak, and P. L. Zinzani, Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup, Ann Oncol, vol.24, issue.6, pp.149-54, 2013.

D. A. Eichenauer, A. Engert, and M. André, Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.70-75, 2014.

K. Adzersen, S. Friedrich, and N. Becker, Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset, J Cancer Res Clin Oncol, vol.142, pp.167-75, 2016.

V. Ehrenstein, I. Petersen, and L. Smeeth, Helping everyone do better: a call for validation studies of routinely recorded health data, Clin Epidemiol, vol.8, pp.49-51, 2016.

S. Singer, J. Das-munshi, and E. Brähler, Prevalence of mental health conditions in cancer patients in acute care-a meta-analysis, 2010.

, Ann Oncol, vol.21, pp.925-930

A. J. Mitchell, M. Chan, and H. Bhatti, Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interviewbased studies, Lancet Oncol, vol.12, issue.11, p.70002, 2011.

P. Brocken, J. B. Prins, P. Dekhuijzen, and H. Van-der-heijden, The faster the better?-a systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways, Psychooncology, vol.21, pp.1-10, 2012.

P. Maguire, Managing psychological morbidity in cancer patients, Eur J Cancer Oxf Engl, vol.36, pp.556-558, 1990.

M. Fisch, Treatment of depression in cancer, J Natl Cancer Inst Monogr, pp.105-111, 2004.

A. Hinz, O. Krauss, and J. P. Hauss, Anxiety and depression in cancer patients compared with the general population, Eur J Cancer Care (Engl), vol.19, pp.522-529, 2010.

M. Reich, La dépression en oncologie, Cancer/Radiothérapie, vol.14, pp.535-538, 2010.

F. Desplenter, C. Bond, and M. Watson, Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study, Br J Cancer, vol.107, pp.1644-1651, 2012.

C. G. Ng, M. P. Boks, and H. M. Smeets, Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands, Psycho-Oncology, vol.22, pp.762-767, 2013.

R. E. Jensen, N. K. Arora, and K. M. Bellizzi, Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma, Cancer, vol.119, pp.672-680, 2013.

S. Oerlemans, F. Mols, and M. R. Nijziel, The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the, 2014.

J. P. Turner, S. Shakib, N. Singhal, J. Hogan-doran, R. Prowse et al., Prevalence and factors associated with polypharmacy in older people with cancer, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.22, pp.1727-1761, 2014.

T. L. Jorgensen, J. Herrstedt, S. Friis, and J. Hallas, Polypharmacy and drug use in elderly Danish cancer patients during 1996 to, J Geriatr Oncol, vol.3, pp.33-40, 2006.

G. S. Smelick, T. P. Heffron, L. Chu, B. Dean, D. A. West et al., Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development, Mol Pharm, vol.10, pp.4055-62, 2013.

S. Mercadante, F. David, S. Riina, and D. Girelli, Injustifiable use of gastroprotection in advanced cancer patients, Palliat Med, vol.21, pp.631-634, 2007.

F. L. Lanza, F. Chan, and E. Quigley, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications, Am J Gastroenterol, vol.104, pp.728-766, 2009.

M. Yang, M. He, M. Zhao, B. Zou, J. Liu et al., Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review, Curr Med Res Opin, vol.2017, pp.1-8

, Haute Autorité de Santé -Les inhibiteurs de la pompe à protons chez l'adulte -Fiche BUM n, 2017.

J. J. Heidelbaugh and J. M. Inadomi, Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients, Am J Gastroenterol, vol.101, pp.2200-2205, 2006.

S. Dial, J. Delaney, .. C. Barkun, A. N. Suissa, and S. , Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease, JAMA, vol.294, pp.2989-95, 2005.

E. Sheen and G. Triadafilopoulos, Adverse effects of long-term proton pump inhibitor therapy, Dig Dis Sci, vol.56, 2011.

A. Tran-duy, B. Spaetgens, A. W. Hoes, N. J. De-wit, and C. Stehouwer, Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.14, pp.1706-1719, 2016.

D. E. Freedberg, L. S. Kim, and Y. Yang, The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association, Gastroenterology, vol.152, pp.706-721, 2017.

. Georgia, PharmacistBarney's LTC PharmacyAugusta

L. Benjamin and . Culpepper, BCPSClinical Pharmacy Educator, Barney's PharmacyClinical Assistant ProfessorUniversity of Georgia College of PharmacyAugusta. Long-Term Consequences of Chronic Proton Pump Inhibitor Use n, PharmDPGY-2Community/Academia Pharmacy ResidentKerr Drug/UNC School of PharmacyChapel Hill, North Carolina John A Galdo, PharmD, 2017.

R. V. Mccaleb, A. S. Gandhi, S. M. Clark, and A. B. Clemmons, Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center

, Ann Pharmacother, vol.50, pp.541-548, 2016.

M. Meli, M. P. Raffa, R. Malta, I. Morreale, L. Aprea et al., The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients, Int J Clin Pharm, vol.37, pp.1152-61, 2015.

G. Numico, V. Fusco, P. Franco, and F. Roila, Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use, Crit Rev Oncol Hematol, vol.111, pp.144-51, 2017.

R. Wedemeyer and H. Blume, Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update, Drug Saf, vol.37, pp.201-212, 2014.

S. Bezabeh, A. C. Mackey, P. Kluetz, D. Jappar, and J. Korvick, Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors, The Oncologist, vol.17, pp.550-554, 2012.

A. Palmaro, G. Moulis, F. Despas, J. Dupouy, and M. Lapeyre-mestre, Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies, Fundam Clin Pharmacol, vol.30, pp.616-640, 2016.

C. Conte, M. Rueter, G. Laurent, R. Bourrel, M. Lapeyre-mestre et al., Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non

, Hodgkin's lymphoma: a cohort study of the French national health insurance database

, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.24, pp.4791-4800, 2016.

C. Conte, A. Palmaro, P. Grosclaude, F. Despas, and M. Lapeyre-mestre, Evaluation of an algorithm to identify incident Non-Hodgkin's lymphoma cases using claims databases with cancer registry. Poster session presented at: Group of Registry and Epidemiology of Cancer in Latin Speaking Countries, 2006.

A. ,

O. S. Van-boxel, M. P. Hagenaars, A. Smout, and P. D. Siersema, Sociodemographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs

, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.7, pp.855-61, 2009.

P. F. Haastrup, M. S. Paulsen, R. D. Christensen, J. Søndergaard, J. M. Hansen et al.,

, Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period, Aliment Pharmacol Ther, vol.44, pp.78-87, 2016.

G. Triadafilopoulos, A. K. Roorda, and J. Akiyama, Indications and safety of proton pump inhibitor drug use in patients with cancer, Expert Opin Drug Saf, vol.12, pp.659-72, 2013.

J. C. Munson, P. M. Wahl, G. Daniel, S. E. Kimmel, and S. Hennessy, Factors associated with the initiation of proton pump inhibitors in corticosteroid users, Pharmacoepidemiol Drug Saf, vol.21, pp.366-74, 2012.

J. Martínek, K. Hlavova, F. Zavada, B. Seifert, S. Rejchrt et al., A surviving myth"--corticosteroids are still considered ulcerogenic by a majority of physicians, Scand J Gastroenterol, vol.45, pp.1156-61, 2010.

J. Luo, C. Chen, T. Ng, Y. Lin, H. Lu et al., Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy

, Br J Clin Pharmacol, vol.68, pp.252-261, 2009.

A. Delcher, S. Hily, A. S. Boureau, G. Chapelet, G. Berrut et al., Multimorbidities and Overprescription of Proton Pump Inhibitors in Older Patients, PloS One, vol.10, p.141779, 2015.

H. O. Conn and T. Poynard, Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy, J Intern Med, vol.236, pp.619-651, 1994.

J. J. Heidelbaugh, A. H. Kim, R. Chang, and P. C. Walker, Overutilization of proton-pump inhibitors: what the clinician needs to know, Ther Adv Gastroenterol, vol.5, pp.219-251, 2012.

M. Riaz, S. Hughes, I. A. Gomez, and R. B. Mortimer, Stress Ulcer Prophylaxis in Hospitalized Patients, Subsequent Use in Primary Care, and Physicians' Opinions About Acid-Suppressive Therapy, South Med J, vol.109, pp.158-64, 2016.

L. S. Muffly, F. J. Hlubocky, N. Khan, K. Wroblewski, K. Breitenbach et al.,

, Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship, Cancer. 15 mars, vol.122, issue.6, pp.954-61, 2016.

M. Mohammadi, T. Moradi, M. Bottai, J. Reutfors, Y. Cao et al., Risk and predictors of attempted and completed suicide in patients with hematological malignancies

, Psychooncology, vol.23, issue.1, pp.1276-82, 2014.

F. Mols, N. K. Aaronson, A. Vingerhoets, J. Coebergh, G. Vreugdenhil et al.,

. Mlm, Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study, Cancer. 15 avr, vol.109, issue.8, pp.1659-67, 2007.

S. K. Smith, S. Zimmerman, C. S. Williams, J. S. Preisser, and E. C. Clipp, Post-Traumatic Stress Outcomes in Non-Hodgkin's Lymphoma Survivors, J Clin Oncol, vol.20, issue.6, pp.934-975, 2008.

S. Oerlemans, F. Mols, M. R. Nijziel, W. P. Zijlstra, J. Coebergh et al., The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry, J Cancer Surviv Res Pract. déc, vol.8, issue.4, pp.555-64, 2014.

D. Oberoi, V. White, J. Seymour, H. M. Prince, S. Harrison et al.,

D. Ng, Y. C. Leong, and G. G. Gan, Quality of life amongst lymphoma survivors in a developing country, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. déc, vol.24, issue.12, pp.5015-5038, 2016.

C. Conte, M. Rueter, G. Laurent, R. Bourrel, M. Lapeyre-mestre et al., Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non

, Hodgkin's lymphoma: a cohort study of the French national health insurance database

, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.24, pp.4791-4800, 2016.

C. G. Ng, S. Mohamed, T. Y. Wern, A. Haris, N. Z. Zainal et al., Comparison of psychotropic prescriptions between oncology and cardiology inpatients: result from a pharmacy database in a teaching hospital in Malaysia, Asian Pac J Cancer Prev APJCP, vol.15, issue.10, pp.4261-4265, 2014.

J. Bezin, M. Duong, R. Lassalle, C. Droz, A. Pariente et al., The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf. 24 mai, 2017.

G. Moulis, M. Lapeyre-mestre, A. Palmaro, G. Pugnet, J. Montastruc et al., French health insurance databases: What interest for medical research, Rev Med Interne. juin

P. Tuppin, L. De-roquefeuil, A. Weill, P. Ricordeau, and Y. Merlière, French national health insurance information system and the permanent beneficiaries sample, Rev Epidemiol Sante Publique. août, vol.58, issue.4, pp.286-90, 2010.

C. Cécile, Evaluation of an algorithm to identify incident Non-Hodgkin's lymphoma cases using claims databases with cancer registry. Conference Poster présenté à: GRELL; 2016 mai, p.137

G. Rey, E. Jougla, A. Fouillet, and D. Hémon, Ecological association between a deprivation index and mortality in France over the period 1997 -2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death, 2009.

A. Bannay, C. Chaignot, P. Blotière, M. Basson, A. Weill et al., The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality, vol.54, pp.188-194, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817541

J. H. Baromètre-santé-;-loge, A. F. Abrahamsen, O. Ekeberg, E. Hannisdal, and S. Kaasa, Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors, Br J Cancer, vol.76, issue.6, pp.791-797, 1997.

R. E. Jensen, N. K. Arora, K. M. Bellizzi, J. H. Rowland, A. S. Hamilton et al.,

, Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma, Cancer. 1 févr, vol.119, issue.3, pp.672-80, 2013.

P. Jennum, L. Baandrup, R. Ibsen, and J. Kjellberg, Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study

, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.11, pp.1906-1919, 2015.

A. Palmaro, J. Dupouy, and M. Lapeyre-mestre, Benzodiazepines and risk of death: Results from two large cohort studies in France and UK, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.10, pp.1566-77, 2015.

N. T. Vozoris, H. D. Fischer, X. Wang, A. L. Stephenson, A. S. Gershon et al.,

, Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD

, Eur Respir J. août, vol.44, issue.2, pp.332-372, 2014.

, Haute Autorité de Santé -ALD n° 30 -Lymphomes non hodgkiniens de l'adulte

, Haute autorité de santé, 2015.

D. Sur,

A. Monnereau, L. Remontet, M. Maynadié, F. Binder-foucard, A. Belot et al., Estimation nationale de l'incidence et de la mortalté par cancer en France entre 1980 et 2012. Partie 2 -Hémopathies malignes, 2013.

D. Sur,

K. R. Shankland, J. O. Armitage, and B. W. Hancock, Non-Hodgkin lymphoma, Lancet Lond Engl. 1 sept, vol.380, issue.9844, pp.848-57, 2012.

R. T. Hoppe, R. H. Advani, W. Z. Ai, R. F. Ambinder, P. Aoun et al., Hodgkin Lymphoma, Version 2, J Natl Compr Cancer, vol.13, issue.5, pp.554-86, 2015.

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012, Int J Cancer, vol.136, issue.5, pp.359-86

. Non-hodgkin, Lymphoma -Cancer Stat Facts

D. Sur,

M. Dandoit, M. Mounier, J. Guy, T. Petrella, S. Girard et al., The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry, Leuk Lymphoma, vol.56, issue.4, pp.1050-1057, 2015.

J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. Coebergh et al., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, Eur J Cancer, vol.49, issue.6, pp.1374-403

L. Guyader-peyrou, S. Belot, A. Maynadié, M. Binder-foucard, F. Remontet et al., Cancer incidence in France over the 1980-2012 period: Hematological malignancies, Rev Epidemiol Sante Publique. avr, vol.64, issue.2, pp.103-115, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580

A. Smith, S. Crouch, S. Lax, J. Li, D. Painter et al., Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network

, Br J Cancer. 28 avr, vol.112, issue.9, pp.1575-84, 2015.

E. Desandes, B. Lacour, A. Belot, F. Molinie, P. Delafosse et al., Cancer incidence and survival in adolescents and young adults in France, Pediatr Hematol Oncol. mai, vol.30, issue.4, pp.291-306, 2000.
URL : https://hal.archives-ouvertes.fr/hal-02168116

L. M. Morton, J. Turner, J. R. Cerhan, M. S. Linet, P. A. Treseler et al., Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph), vol.110, pp.695-708, 2007.

E. S. Jaffe, L. Harris, N. Stein, H. Vardiman, and J. , Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues -Google Livres, 2001.

D. Sur,

P. Grosclaude, L. Remontet, A. Belot, A. Danzon, N. Rasamimanana et al., Survie nette des personnes atteintes de cancer en France, 1989.

D. Sur,

E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein et al., The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood. 12 mai, vol.117, pp.5019-5051, 2011.

J. J. Turner, L. M. Morton, M. S. Linet, C. A. Clarke, M. E. Kadin et al., InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions, vol.116, 2010.

A. Monnereau, X. Troussard, A. Belot, A. Guizard, A. Woronoff et al., Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in FranceMonnereau -2012 -International Journal of Cancer -Wiley Online Library, vol.132, pp.2378-87, 2013.

N. Asano, K. Iijima, T. Koike, A. Imatani, and T. Shimosegawa, Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review, World J Gastroenterol. 14 juill, vol.21, issue.26, pp.8014-8034, 2015.

E. Baecklund, K. E. Smedby, L. Sutton, J. Askling, and R. Rosenquist, Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?, Semin Cancer Biol. févr, vol.24, pp.61-70, 2014.

A. Krishnan and J. A. Zaia, HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options, Hematol Am Soc Hematol Educ Program. 5 déc, vol.2014, issue.1, pp.584-593, 2014.

G. Nocturne and X. Mariette, Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management, Br J Haematol. févr, vol.168, issue.3, pp.317-344, 2015.

S. Paydas, Hepatitis C virus and lymphoma, Crit Rev Oncol Hematol. mars, vol.93, issue.3, pp.246-56, 2015.

C. Visco and S. Finotto, Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment, World J Gastroenterol. 28 août, vol.20, issue.32, pp.11054-61, 2014.

M. Vockerodt, L. Yap, C. Shannon-lowe, H. Curley, W. Wei et al., The Epstein-Barr virus and the pathogenesis of lymphoma, J Pathol. janv, vol.235, issue.2, pp.312-334, 2015.

Y. Wang and S. Ma, Risk factors for etiology and prognosis of mantle cell lymphoma, Expert Rev Hematol. avr, vol.7, issue.2, pp.233-276, 2014.

B. Chiu and D. D. Weisenburger, An update of the epidemiology of non-Hodgkin's lymphoma, Clin Lymphoma. déc, vol.4, issue.3, pp.161-169, 2003.

J. H. Mandel, M. A. Kelsh, P. J. Mink, D. D. Alexander, R. M. Kalmes et al., Occupational trichloroethylene exposure and non-Hodgkin's lymphoma: a meta-analysis and review, Occup Environ Med. sept, vol.63, issue.9, pp.597-607, 2006.

P. Cocco, G. Satta, S. Dubois, C. Pili, M. Pilleri et al., Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study, Occup Environ Med. févr, vol.70, issue.2, pp.91-99, 2013.

L. Schinasi and M. E. Leon, Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis, Int J Environ Res Public Health. 23 avr, vol.11, issue.4, pp.4449-527, 2014.

S. M. Ansell, Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management, Am J Hematol. juill, vol.89, issue.7, pp.771-780, 2014.

J. O. Armitage, R. D. Gascoyne, M. A. Lunning, and F. Cavalli, Non-Hodgkin lymphoma. The Lancet, vol.15, pp.298-310, 10091.

A. Buzyn, Les apports des Plans cancer à la cancérologie. Oncologie [Internet]. sept, vol.16, pp.4-6, 2014.

. Groupe and . Hématomip, Oncomip -Référentiel-Traitement des lymphomes de l'adulte, 2012.

D. Sur,

G. De-travail and O. , , 2013.

R. Willemze, E. Hodak, P. L. Zinzani, L. Specht, M. Ladetto et al., Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. oct, vol.24, issue.6, pp.149-154, 2013.

M. Dreyling, E. Campo, O. Hermine, M. Jerkeman, L. Gouill et al., Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup, Ann Oncol Off J Eur Soc Med Oncol. 1 juill, vol.28, issue.suppl_4, pp.62-71, 2017.

M. Dreyling, M. Ghielmini, S. Rule, G. Salles, U. Vitolo et al., Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis

, Ann Oncol Off J Eur Soc Med Oncol. 19 févr, 2017.

U. Vitolo, J. F. Seymour, M. Martelli, G. Illerhaus, T. Illidge et al., Extranodal diffuse large Bcell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.27, issue.5, pp.91-102, 2016.

F. D'amore, P. Gaulard, L. Trümper, P. Corradini, W. Kim et al., Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.26, issue.5, pp.108-115, 2015.

M. Dreyling, C. Geisler, O. Hermine, H. C. Kluin-nelemans, L. Gouill et al., Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.25, issue.3, pp.83-92, 2014.

D. A. Eichenauer, A. Engert, M. André, M. Federico, T. Illidge et al., Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.25, issue.3, pp.70-75, 2014.

M. Ghielmini, U. Vitolo, E. Kimby, S. Montoto, J. Walewski et al., ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), Ann Oncol Off J Eur Soc Med Oncol. mars, vol.24, issue.3, pp.561-76, 2013.

B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med. 24 janv, vol.346, issue.4, pp.235-277, 2002.

D. T. Nguyen, J. Hendry, H. Amess, L. Doughty, and L. W. Diamond, IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients -Nguyen -2009 -European Journal of Haematology -Wiley Online Library, Disponible sur, vol.62, pp.76-82, 1999.

E. Ballatori, F. Roila, B. Ruggeri, M. Betti, S. Sarti et al., The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer [Internet]. 1 févr, vol.15, pp.179-85, 2007.

E. K. Choi, I. Kim, O. Chang, D. Kang, S. Nam et al., Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients, Psychooncology [Internet]. 1 mars, 2014.

N. Mounier, N. Heutte, C. Thieblemont, J. Briere, P. Gaulard et al., Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial, Clin Lymphoma Myeloma Leuk. juin, vol.12, issue.3, pp.151-155, 2012.

S. Anthony, P. Hebel, A. Garrel, V. Oliveri, C. Thieblemont et al., Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment, Bull Cancer, vol.104, issue.3, pp.221-252, 2017.

B. Coiffier, C. Thieblemont, E. Van-den-neste, G. Lepeu, I. Plantier et al., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte, Blood [Internet], vol.116, issue.12, pp.2040-2045, 2010.

P. Feugier, A. Van-hoof, C. Sebban, P. Solal-celigny, R. Bouabdallah et al., Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte, Journal of Clinical Oncology, vol.23, issue.18, pp.4117-4143, 2005.

D. Pulte, A. Gondos, and . Brenner-hermann, Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century, Arch Intern Med, vol.168, issue.5, pp.469-76, 2008.

P. Mclaughlin, A. Grillo-lopez, B. Link, R. Levy, M. Czuczman et al., Rituximab chimeric anti-CD20 monoclonal antibod, J Clin Oncol, vol.16, issue.8, pp.2825-2858, 1998.

M. C. Palanca-wessels and O. W. Press, Advances in the treatment of hematologic malignancies using immunoconjugates, Blood. 10 avr, vol.123, issue.15, pp.2293-301, 2014.

, Hodgkin Lymphoma -Cancer Stat Facts

D. Sur,

J. M. Goldman and J. V. Melo, Chronic myeloid leukemia--advances in biology and new approaches to treatment, N Engl J Med, vol.349, issue.15, pp.1451-64, 2003.

S. K. Kumar, S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman et al., Improved survival in multiple myeloma and the impact of novel therapies, Blood. 1 mars, vol.111, issue.5, pp.2516-2536, 2008.

A. Hamilton, P. Gallipoli, E. Nicholson, and T. L. Holyoake, Targeted therapy in haematological malignancies, J Pathol. mars, vol.220, issue.4, pp.404-422, 2010.

T. Seiler, G. Hutter, and M. Dreyling, The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date, Drugs [Internet]. 1 avr, vol.76, issue.6, pp.639-685, 2016.

A. Piggin, E. Bayly, and C. S. Tam, Novel agents versus chemotherapy as frontline treatment of CLL, Leuk Lymphoma. juin, vol.58, issue.6, pp.1320-1324, 2017.

S. Puvvada, S. Kendrick, and L. Rimsza, Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma, Cancer Genet. août, vol.206, issue.7-8, pp.257-65, 2013.

N. Freemantle, L. Marston, K. Walters, J. Wood, M. R. Reynolds et al., Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research, BMJ, vol.347, issue.11, 2013.

W. B. Al-refaie, S. M. Vickers, W. Zhong, H. Parsons, D. Rothenberger et al., Cancer trials versus the real world in the United States, Ann Surg. sept, vol.254, issue.3, pp.442-443, 2011.

K. Kwiatkowski, K. Coe, J. C. Bailar, and G. M. Swanson, Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?, Cancer. 15 août, vol.119, issue.16, pp.2956-63, 2013.

L. T. Penberthy, B. A. Dahman, V. I. Petkov, and J. P. Deshazo, Effort required in eligibility screening for clinical trials, J Oncol Pract, vol.8, issue.6, pp.365-70, 2012.

D. Sur,

G. Moulis, M. Lapeyre-mestre, A. Palmaro, G. Pugnet, J. Montastruc et al., French health insurance databases: What interest for medical research, Rev Med Interne. juin, vol.36, issue.6, pp.411-418, 2015.

, Résultats de la recherche -Ministère des Solidarités et de la Santé

D. Sur,

G. Moulis, A. Palmaro, J. Montastruc, B. Godeau, M. Lapeyre-mestre et al., Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, vol.124, issue.22, pp.3308-3323, 2014.

G. Moulis, J. Germain, D. Adoue, O. Beyne-rauzy, H. Derumeaux et al., Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database, Eur J Intern Med. juill, vol.32, pp.21-22, 2016.

G. Moulis, A. Palmaro, L. Sailler, and M. Lapeyre-mestre, Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study, PLoS ONE, vol.10, issue.11, 2015.

M. Goldberg, M. Carton, A. Doussin, A. Fagot-campagna, E. Heyndrickx et al.,

, Rev Epidemiol Sante Publique, vol.65, issue.4, pp.144-152, 2017.

A. Bannay, C. Chaignot, P. Blotière, M. Basson, A. Weill et al., The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality. Med Care, vol.54, pp.188-194
URL : https://hal.archives-ouvertes.fr/hal-01817541

P. Tuppin, J. Rudant, P. Constantinou, C. Gastaldi-ménager, A. Rachas et al., Value of a national administrative database to guide public decisions: From the système national, p.161

, Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France, Rev Epidemiol Sante Publique. 26 juill, 2017.

B. L. Strom, Data validity issues in using claims data, Pharmacoepidemiol Drug Saf. sept, vol.10, issue.5, pp.389-92, 2001.

, Public Policy Committee IS of P. Guidelines for good pharmacoepidemiology practice (GPP)

, Pharmacoepidemiol Drug Saf, vol.1, issue.2016, pp.2-10

P. C. Souverein, V. Abbing-karahagopian, M. E. Huerta, C. De-abajo, F. Leufkens et al., Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures, Pharmacoepidemiol Drug Saf. mars, vol.25, issue.1, pp.88-102, 2016.

V. Abbing-karahagopian, X. Kurz, F. De-vries, T. P. Van-staa, Y. Alvarez et al., Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project, Curr Clin Pharmacol. mai, vol.9, issue.2, pp.130-138, 2014.

D. Madigan, P. B. Ryan, and M. Schuemie, Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies, Ther Adv Drug Saf. avr, vol.4, issue.2, pp.53-62, 2013.

W. A. Ray, P. B. Thapa, and G. P. , Misclassification of current benzodiazepine exposure by use of a single baseline measurement and its effects upon studies of injuries, Pharmacoepidemiol Drug Saf. déc, vol.11, issue.8, pp.663-672, 2002.

P. Chyou, Patterns of bias due to differential misclassification by case-control status in a casecontrol study, Eur J Epidemiol, vol.22, issue.1, pp.7-17, 2007.

A. Correa-villaseñor, W. F. Stewart, F. Franco-marina, and H. Seacat, Bias from nondifferential misclassification in case-control studies with three exposure levels, Epidemiol Camb Mass. mai, vol.6, issue.3, pp.276-81, 1995.

N. J. Birkett, Effect of nondifferential misclassification on estimates of odds ratios with multiple levels of exposure, Am J Epidemiol. 1 août, vol.136, issue.3, pp.356-62, 1992.

T. L. Lash, M. P. Fox, R. F. Maclehose, G. Maldonado, L. C. Mccandless et al., Good practices for quantitative bias analysis, Int J Epidemiol. déc, vol.43, issue.6, pp.1969-85, 2014.

A. Palmaro, Q. Boucherie, J. Dupouy, J. Micallef, and M. Lapeyre-mestre, Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?, Pharmacoepidemiol Drug Saf. mai, vol.26, issue.5, pp.544-53, 2017.

C. Quantin, E. Benzenine, M. Hägi, B. Auverlot, M. Abrahamowicz et al., Estimation of national colorectal-cancer incidence using claims databases, J Cancer Epidemiol, p.298369, 2012.

I. Baldi, P. Vicari, D. Cuonzo, D. Zanetti, R. Pagano et al., A high positive predictive value algorithm using hospital administrative data identified incident cancer cases, J Clin Epidemiol, vol.61, issue.4, pp.373-382, 2008.

F. Olive, F. Gomez, A. Schott, L. Remontet, N. Bossard et al., Critical analysis of French DRG based information system (PMSI) databases for the epidemiology of cancer

, Rev Dépidémiologie Santé Publique. févr, vol.59, issue.1, pp.53-61, 2011.

N. Mitton, M. Colonna, B. Trombert, F. Olive, F. Gomez et al., A Suitable Approach to Estimate Cancer Incidence in Area without Cancer Registry, J Cancer Epidemiol, p.418968, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00698065

O. Ganry, A. Taleb, J. Peng, N. Raverdy, and A. Dubreuil, Evaluation of an algorithm to identify incident breast cancer cases using DRGs data, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. août, vol.12, issue.4, pp.295-304, 2003.

C. M. Couris, A. Seigneurin, S. Bouzbid, M. Rabilloud, P. Perrin et al., French claims data as a source of information to describe cancer incidence: predictive values of two identification methods of incident prostate cancers, J Med Syst. déc, vol.30, issue.6, pp.459-63, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00427927

L. Remontet, N. Mitton, C. M. Couris, J. Iwaz, F. Gomez et al., Is it possible to estimate the incidence of breast cancer from medico-administrative databases?, Eur J Epidemiol, vol.23, issue.10, pp.681-689, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00338952

Z. Hafdi-nejjari, C. Couris, A. Schott, A. Schot, L. Perrot et al., Role of hospital claims databases from care units for estimating thyroid cancer incidence in the Rhône-Alpes region of France

, Rev Dépidémiologie Santé Publique, vol.54, pp.391-399, 2006.

N. Carré, Z. Uhry, M. Velten, B. Trétarre, C. Schvartz et al., Predictive value and sensibility of hospital discharge system (PMSI) compared to cancer registries for thyroïd cancer, Rev Dépidémiologie Santé Publique. sept, vol.54, issue.4, pp.367-76, 1999.

S. Setoguchi, D. H. Solomon, R. J. Glynn, E. F. Cook, R. Levin et al., Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data, Cancer Causes Control CCC. juin, vol.18, issue.5, pp.561-570, 2007.

A. Palmaro, M. Gauthier, C. Conte, P. Grosclaude, F. Despas et al., Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry, Medicine (Baltimore). mars, vol.96, issue.12, p.6189, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01907563

P. Avillach, P. M. Coloma, R. Gini, M. Schuemie, F. Mougin et al., Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project, J Am Med Inform Assoc JAMIA. 1 janv, vol.20, issue.1, pp.184-92, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01135052

V. Ehrenstein, I. Petersen, L. Smeeth, S. S. Jick, E. I. Benchimol et al., Helping everyone do better: a call for validation studies of routinely recorded health data, Clin Epidemiol, vol.8, pp.49-51, 2016.

P. Encepp-home,

, Registre des cancers du Tarn (registre qualifié 2010-2013) / Portail Epidemiologie -France | Health Databases

D. Sur,

R. A. Herman, B. Gilchrist, B. K. Link, and R. Carnahan, A systematic review of validated methods for identifying lymphoma using administrative data, Pharmacoepidemiol Drug Saf. janv, vol.21, issue.1, pp.203-215, 2012.

S. Lamy, M. Rueter, P. Jeanneau, J. Nogaro, M. Lapeyre-mestre et al., The effect of an ambulatory medical assistance during chemotherapy and follow-up among patient with diffuse large B-cell lymphoma on treatment adherence, J Clin Oncol, vol.32, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01933497

R. Caruso, L. Grassi, M. G. Nanni, and M. Riba, Psychopharmacology in psycho-oncology, Curr Psychiatry Rep. sept, vol.15, issue.9, p.393, 2013.

F. Desplenter, C. Bond, M. Watson, C. Burton, P. Murchie et al., Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study, British Journal of Cancer, vol.107, pp.1644-51, 2012.

C. G. Ng, M. P. Boks, H. M. Smeets, N. Z. Zainal, and N. J. Wit, Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands, Psycho-Oncology, vol.1, issue.2013, pp.762-769

. Briot-m, Rapport sur le bon usage des médicaments psychotropes, Juin, 2006.

A. Disponible-sur-;-desplanques-leperre, R. Dhoyen, N. Legrain, S. Degos, and L. , Améliorer la prescription des psychotropes chez le sujet âgé, une démarche participative de la Haute autorité de santé. Numéro thématique. La santé mentale en France, surveillance et enjeux, p.328, 2008.

D. Sur, Reich M. La dépression en oncologie. Cancer/Radiothérapie, 2010.

E. Obiora, R. Hubbard, R. D. Sanders, and P. R. Myles, The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a populationbased cohort, Thorax. févr, vol.68, issue.2, pp.163-70, 2013.

S. Singer, J. Das-munshi, and E. Brähler, Prevalence of mental health conditions in cancer patients in acute care-a meta-analysis, Ann Oncol, vol.21, issue.5, 2010.

C. Edwrads, J. Bushnell, C. Ashton, and M. Rawlins, Hospital prescribing and usage of hypnotics and anxiolytics, British Journal of clinical pharmacology, 1911.

N. P. Suppli, I. Deltour, L. H. Damkjaer, J. Christensen, A. B. Jensen et al., Factors associated with the prescription of antidepressive medication to breast cancer patients, Acta Oncol Stockh Swed. févr, vol.50, issue.2, pp.243-51, 2011.

I. Forgacs and A. Loganayagam, Overprescribing proton pump inhibitors, BMJ. 5 janv, vol.336, issue.7634, pp.2-3, 2008.

L. Thomas, E. J. Culley, P. Gladowski, V. Goff, J. Fong et al., Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization, J Manag Care Pharm JMCP. mars, vol.16, issue.2, pp.122-131, 2010.

J. J. Heidelbaugh and J. M. Inadomi, Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients, Am J Gastroenterol. oct, vol.101, issue.10, pp.2200-2205, 2006.

J. J. Heidelbaugh, D. C. Metz, and Y. Yang, Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?, Int J Clin Pract, vol.66, issue.6, pp.582-91, 2012.

S. Morini, A. Zullo, D. Oliveti, A. Chiriatti, R. Marmo et al., A very high rate of inappropriate use of gastroprotection for nonsteroidal anti-inflammatory drug therapy in primary care: a cross-sectional study, J Clin Gastroenterol, vol.45, issue.9, pp.780-784, 2011.

F. Lodato, E. Poluzzi, E. Raschi, C. Piccinni, A. Koci et al., Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy, Eur J Intern Med. mai, vol.30, pp.31-37, 2016.

C. Scarpignato, L. Gatta, A. Zullo, C. Blandizzi, and S. Group, Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases -A position paper addressing benefits and potential harms of acid suppression, BMC Med, vol.14, issue.1, p.179, 2016.

V. Savarino, P. Dulbecco, N. De-bortoli, A. Ottonello, and E. Savarino, The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal, Eur J Intern Med, vol.37, pp.19-24, 2017.

E. Sheen and G. Triadafilopoulos, Adverse effects of long-term proton pump inhibitor therapy, Dig Dis Sci. avr, vol.56, issue.4, pp.931-50, 2011.

G. Lwo-pharmdclinical-pharmacistbarney's-ltc-pharmacyaugusta, G. Benjamin, and L. Culpepper, PharmDPGY-2Community/Academia Pharmacy ResidentKerr Drug/UNC School of PharmacyChapel Hill, North Carolina John A Galdo, PharmD, BCPSClinical Pharmacy Educator, Barney's PharmacyClinical Assistant ProfessorUniversity of Georgia College of PharmacyAugusta. LongTerm Consequences of Chronic Proton Pump Inhibitor Use

D. Sur,

R. V. Mccaleb, A. S. Gandhi, S. M. Clark, and A. B. Clemmons, Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center, Ann Pharmacother. juill, vol.50, issue.7, pp.541-548, 2016.

G. Triadafilopoulos, A. K. Roorda, and J. Akiyama, Indications and safety of proton pump inhibitor drug use in patients with cancer, Expert Opin Drug Saf. sept, vol.12, issue.5, pp.659-72, 2013.

J. Martínek, K. Hlavova, F. Zavada, B. Seifert, S. Rejchrt et al., « A surviving myth »--corticosteroids are still considered ulcerogenic by a majority of physicians, Scand J Gastroenterol, vol.45, issue.10, pp.1156-61, 2010.

J. Luo, C. Chen, T. Ng, Y. Lin, H. Lu et al., Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy, Br J Clin Pharmacol. août, vol.68, issue.2, pp.252-261, 2009.

A. Delcher, S. Hily, A. S. Boureau, G. Chapelet, G. Berrut et al., Multimorbidities and Overprescription of Proton Pump Inhibitors in Older Patients, PloS One, vol.10, issue.11, p.141779, 2015.

H. O. Conn and T. Poynard, Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy, J Intern Med. déc, vol.236, issue.6, pp.619-651, 1994.

J. J. Heidelbaugh, A. H. Kim, R. Chang, and P. C. Walker, Overutilization of proton-pump inhibitors: what the clinician needs to know, Ther Adv Gastroenterol. juill, vol.5, issue.4, pp.219-251, 2012.

C. Conte, M. Rueter, G. Laurent, R. Bourrel, M. Lapeyre-mestre et al., Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.24, pp.4791-4800, 2016.

D. Sur,

J. H. Loge, A. F. Abrahamsen, O. Ekeberg, E. Hannisdal, and S. Kaasa, Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors, Br J Cancer, vol.76, issue.6, pp.791-797, 1997.

S. Oerlemans, F. Mols, M. R. Nijziel, W. P. Zijlstra, and J. Coebergh, Poll-Franse LV van de. The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry, J Cancer Surviv

, , vol.8, pp.555-64

R. E. Jensen, N. K. Arora, K. M. Bellizzi, J. H. Rowland, A. S. Hamilton et al., Health-Related Quality of Life Among Survivors of Aggressive Non-Hodgkin Lymphoma, vol.1, pp.672-80

P. Jennum, L. Baandrup, R. Ibsen, and J. Kjellberg, Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.11, pp.1906-1919, 2015.

N. T. Vozoris, H. D. Fischer, X. Wang, A. L. Stephenson, A. S. Gershon et al., Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD, Eur Respir J. août, vol.44, issue.2, pp.332-372, 2014.

D. F. Kripke, R. D. Langer, and L. E. Kline, Hypnotics' association with mortality or cancer: a matched cohort study, BMJ Open, vol.2, issue.1, p.850, 2012.

S. Weich, H. L. Pearce, P. Croft, S. Singh, I. Crome et al., Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study, BMJ. 19 mars, vol.348, p.1996, 2014.

M. Baumann, E. Spitz, F. Guillemin, J. Ravaud, M. Choquet et al., Associations of social and material deprivation with tobacco, alcohol, and psychotropic drug use, and gender: a population-based study, Int J Health Geogr, vol.6, p.50, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00433008

A. B. Chen, Y. Feng, D. Neuberg, C. Recklitis, L. R. Diller et al., Employment and insurance in survivors of Hodgkin lymphoma and their siblings: a questionnaire study, Leuk Lymphoma. août, vol.53, issue.8, pp.1474-80, 2012.

I. Glimelius, S. Ekberg, J. Linderoth, M. Jerkeman, E. T. Chang et al., Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a populationbased comparative study, J Cancer Surviv Res Pract. déc, vol.9, issue.4, pp.599-609, 2015.

F. Mols, M. Thong, P. Vissers, T. Nijsten, and L. V. Van-de-poll-franse, Socio-economic implications of cancer survivorship: results from the PROFILES registry, Eur J Cancer Oxf Engl, vol.48, issue.13, pp.2037-2079, 1990.

S. Oerlemans, F. Mols, M. R. Nijziel, M. Lybeert, and L. V. Van-de-poll-franse, The impact of treatment, sociodemographic and clinical characteristics on health-related quality of life among Hodgkin's and nonHodgkin's lymphoma survivors: a systematic review, Ann Hematol. sept, vol.90, issue.9, pp.993-1004, 2011.

M. Jefford, A. C. Ward, K. Lisy, K. Lacey, J. D. Emery et al., Patient-reported outcomes in cancer survivors: a population-wide cross-sectional study. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, 2017.

L. A. Daniëls, S. Oerlemans, A. Krol, C. L. Creutzberg, and L. V. Van-de-poll-franse, Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity, Br J Cancer. 18 févr, vol.110, issue.4, pp.868-74, 2014.

O. Husson, S. Oerlemans, F. Mols, R. Smeets, P. M. Poortmans et al., Satisfaction with information provision is associated with baseline but not with follow-up quality of life among lymphoma patients: Results from the PROFILES registry, Acta Oncol Stockh Swed. juill, vol.53, issue.7, pp.917-943, 2014.

S. Oerlemans, O. Husson, F. Mols, P. Poortmans, H. Roerdink et al., Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors--results from a Dutch population-based study, Ann Hematol, vol.91, issue.10, pp.1587-95, 2012.

B. Zeller, J. H. Loge, A. Kanellopoulos, H. Hamre, V. B. Wyller et al., Chronic fatigue in long-term survivors of childhood lymphomas and leukemia: persistence and associated clinical factors, J Pediatr Hematol Oncol. août, vol.36, issue.6, pp.438-482, 2014.

R. Zordan, V. Manitta, H. Nandurkar, M. Cole-sinclair, and J. Philip, Prevalence and predictors of fatigue in haemo-oncological patients, Intern Med J. oct, vol.44, issue.10, pp.1013-1020, 2014.

L. Arts, L. V. Van-de-poll-franse, S. W. Van-den-berg, J. B. Prins, O. Husson et al., Lymphoma InterVEntion (LIVE) -patient-reported outcome feedback and a web-based self-management intervention for patients with lymphoma: study protocol for a randomised controlled trial, Trials. 28 avr, vol.18, issue.1, p.199, 2017.

G. Compaci, M. Rueter, S. Lamy, L. Oberic, C. Recher et al., Ambulatory Medical Assistance--After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy, BMC Cancer, vol.15, p.781, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01912614

G. Compaci, L. Ysebaert, L. Obéric, H. Derumeaux, and G. Laurent, Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: the Ambulatory Medical Assistance (AMA) experience, Int J Nurs Stud, 2011.

, INVSIncidence et survie des hémopathies malignes: données générales et situation chez les plus de 75 ans, 1989.

. Invs, Projections de l'incidence et de la mortalité par cancer en France en 2011. Myélome multiple et maladie immunoproliférative, 2016.

S. K. Kumar, S. V. Rajkumar, and A. Dispenzieri, Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, pp.2516-2536, 2008.

K. L. Schulman, K. Berenson, and Y. Shih, A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR Oncology Good Outcomes Research Practices Working Group, Value Health, vol.16, pp.655-69, 2013.

D. G. Manuel, L. C. Rosella, and T. A. Stukel, Importance of accurately identifying disease in studies using electronic health records, BMJ, vol.341, p.4226, 2010.

V. Ehrenstein, I. Petersen, and L. Smeeth, Helping everyone do better: a call for validation studies of routinely recorded health data, Clin Epidemiol, vol.8, pp.49-51, 2016.

Z. Hafdi-nejjari, C. Couris, and A. Schott, Role of hospital claims databases from care units for estimating thyroid cancer incidence in the Rhône-Alpes region of France, Rev Epidemiol Sante Pub, vol.54, pp.391-399, 2006.

G. Coureau, I. Baldi, and M. Savès, Performance evaluation of hospital claims database for the identification of incident central nervous system tumors compared with a cancer registry, Rev Epidemiol Sante Pub, vol.60, pp.295-304, 2004.

C. Quantin, E. Benzenine, and M. Hagi, Estimation of national colorectalcancer incidence using claims databases, J Cancer Epidemiol, vol.2012, p.298369, 2012.

, Registre des cancers du Tarn. Health Databases. Available at, 2016.

C. Percy, A. Fritz, and A. Jack, International Classification of Diseases for Oncology, 2000.

J. E. Tyczynski, E. Demaret, and D. M. Parkin, Standards and guidelines for cancer registration in Europe. The ENCR recommendations, International Agency for Research on Cancer, vol.1, 2003.

G. Moulis, M. Lapeyre-mestre, and A. Palmaro, French health insurance databases: what interest for medical research, Rev Med Interne, vol.36, pp.411-418, 2014.

J. Chubak, G. Pocobelli, and N. S. Weiss, Trade-offs between accuracy measures for electronic healthcare data algorithms, J Clin Epidemiol, vol.65, pp.343-352, 2012.

P. M. Bossuyt, J. B. Reitsma, and D. E. Bruns, The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration, Ann Intern Med, vol.138, pp.1-2, 2003.

E. I. Benchimol, D. G. Manuel, and T. To, Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data, J Clin Epidemiol, vol.64, pp.821-830, 2011.

A. Teitelbaum, A. Ba-mancini, and H. Huang, Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data, Oncologist, vol.18, pp.37-45, 2013.

B. M. Craig, D. E. Rollison, and A. F. List, Underreporting of myeloid malignancies by United States cancer registries, Cancer Epidemiol Biomarkers Prev, vol.21, pp.474-81, 2012.

C. R. Cogle, B. M. Craig, and D. E. Rollison, Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries, Blood, vol.117, pp.7121-7126, 2011.

P. Grosclaude, C. Dentan, and B. Trétarre, Relevance of health administrative databases in cancer surveillance. Comparison with registries records at individual level, Bull Epidemiol Hebd, pp.63-70, 2012.

, Algorithme de sélection des hospitalisations liées à la prise en charge du cancer dans les bases nationales d'activité hospitalière de court séjour, 2016.

P. Avillach, P. M. Coloma, and R. Gini, Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project, J Am Med Inform Assoc, vol.20, pp.184-92, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01135052

R. A. Herman, B. Gilchrist, and B. K. Link, A systematic review of validated methods for identifying lymphoma using administrative data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.203-215, 2012.

S. E. Andrade, L. R. Harrold, and J. Tjia, A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.100-128, 2012.

G. Schneider, S. Kachroo, and N. Jones, A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens-Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.236-245, 2012.

G. Schneider, S. Kachroo, and N. Jones, A systematic review of validated methods for identifying hypersensitivity reactions other than anaphylaxis (fever, rash, and lymphadenopathy), using administrative and claims data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.248-55, 2012.

R. M. Carnahan, K. G. Moores, and E. N. Perencevich, A systematic review of validated methods for identifying infection related to blood products, tissue grafts, or organ transplants using administrative data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.213-234, 2012.

V. R. Kee, B. Gilchrist, and M. A. Granner, A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.183-93, 2012.

J. T. Walkup, L. Townsend, and S. Crystal, A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.174-82, 2012.

S. E. Williams, R. Carnahan, and S. Krishnaswami, A systematic review of validated methods for identifying transverse myelitis using administrative or claims data, Vaccine, vol.31, issue.10, pp.83-90, 2013.

N. Princic, G. Chris, and T. Willson, Development of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data, 57th American Society of Hematology Annual Meeting, pp.5-8, 2015.

. Palmaro, , vol.96, p.12, 2017.

E. Roman and A. G. Smith, Epidemiology of lymphomas, Histopathology, vol.58, issue.1, pp.4-14, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00610747

J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. Coebergh et al., Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 2013.

, , vol.49, pp.1374-403

A. Monnereau, Z. Uhry, N. Bossard, A. Cowppli-bony, N. Voirin et al., Survie des personnes atteintes de cancer en France métropolitaine, 1989-2013. Partie 2 -Hémopathies malignes

D. Chihara, L. J. Nastoupil, J. N. Williams, P. Lee, J. L. Koff et al., New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy, Expert Rev Anticancer Ther, vol.15, issue.5, pp.531-575, 2015.

S. M. Ansell and J. Armitage, Non-Hodgkin lymphoma: diagnosis and treatment, Mayo Clin Proc, 2005.

S. M. Ansell, Non-Hodgkin Lymphoma: Diagnosis and Treatment, Mayo Clin Proc, vol.90, issue.8, pp.1152-63, 2015.

P. M. Kasi, H. A. Tawbi, C. V. Oddis, and H. S. Kulkarni, Clinical review: Serious adverse events associated with the use of rituximab -a critical care perspective. Crit Care, vol.16, p.231, 2012.

J. Devlen, P. Maguire, P. Phillips, and D. Crowther, Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study, Br Med J (Clin Res Ed, vol.295, issue.6604, pp.955-962, 1987.

E. Mojs, K. Warchol-biedermann, and W. Sanborski, What Do We Know About Psychological Outcomes of Lymphoma in Adults, European Psychologist, vol.22, pp.121-131, 2017.

S. Byford, D. J. Torgerson, and J. Raftery, Economic note: cost of illness studies, BMJ, vol.320, p.1335, 2000.

M. A. Koopmanschap, Useful for health policy?, PharmacoEconomics, vol.14, pp.143-148, 1998.

J. H. Best, J. Hornberger, S. J. Proctor, L. F. Omnes, and F. Jost, Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health, vol.8, pp.462-70, 2005.

S. Khor, J. Beca, and M. Krahn, Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer, vol.14, p.586, 2014.

E. Sabater, A. López-guillermo, A. Rueda, A. Salar, I. Oyagüez et al., Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Appl Health Econ Health Policy, vol.14, pp.465-477, 2016.

E. Deconinck, H. Miadi-fargier, C. L. Pen, and P. Brice, Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation, Pharmacoeconomics, vol.28, issue.1, pp.35-46, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00484797

C. Burudpakdee, H. M. Lin, and W. Wang, Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data, J Med Econ, vol.19, issue.10, pp.965-72, 2016.

G. Moulis, M. Lapeyre-mestre, A. Palmaro, G. Pugnet, J. Montastruc et al., French health insurance databases: What interest for medical research, Rev Med Interne, vol.36, issue.6, pp.411-418, 2015.

C. Conte, A. Palmaro, P. Grosclaude, L. Daubisse-marliac, F. Despas et al., A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases. Medicine (Baltimore), vol.97, p.9418, 2018.

, Anatomical Therapeutic Chemical Classification, 2017.

A. Bannay, C. Chaignot, P. O. Blotière, M. Basson, A. Weill et al., The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality, Med Care, vol.54, issue.2, pp.188-94, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817541

T. D. Diciccio and B. Efron, Bootstrap confidence intervals, vol.11, pp.189-228, 1996.

F. Tuerlinckx, F. Rijmen, G. Verbeke, D. Boeck, and P. , Statistical inference in generalized linear mixed models: a review, Br J Math Stat Psychol, vol.59, issue.2, pp.225-55, 2006.

L. Liu, M. E. Cowen, R. L. Strawderman, T. Ya-chen, and . Shih, A Flexible Two-Part Random Effects Model for Correlated Medical Costs J Health Econ, vol.29, pp.110-123, 2010.

P. W. Auweiler, D. Müller, S. Stock, and A. Gerber, Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review, Pharmacoeconomics, vol.30, issue.7, pp.537-586, 2012.

C. Knight and F. Maciver, The cost-effectiveness of rituximab in non-Hodgkin's lymphoma. Expert Rev Pharmacoecon Outcomes Res, vol.7, pp.319-345, 2007.

M. Van-agthoven, C. A. Uyl-de-groot, P. Sonneveld, and A. Hagenbeek, Economic assessment in the management of non-Hodgkin's lymphoma, Expert Opin Pharmacother, vol.5, issue.12, pp.2529-2577, 2004.

T. Foster, J. D. Miller, M. E. Boye, and M. W. Russell, Economic burden of follicular non-Hodgkin's lymphoma, Pharmacoeconomics, vol.27, issue.8, pp.657-79, 2009.

C. Gisselbrecht, B. Glass, N. Mounier, S. Gill, D. Linch et al., Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, vol.28, issue.27, pp.4184-90, 2010.

B. Coiffier, E. Lepage, and J. Briere, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, vol.346, pp.235-277, 2002.

G. Salles, J. F. Seymour, and F. Offner, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, vol.377, pp.42-51, 2011.

M. H. Van-oers, M. Van-glabbeke, and L. Giurgea, Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study, J Clin Oncol, vol.28, pp.2853-2861, 2010.

, Référentiel Oncomip 2017 Traitement des Lymphomes de l'Adulte, Oncomip treatment guideline of adult lymphomas, 2017.

. Boffetta and J. M. Kaldor, Secondary malignancies following cancer chemotherapy, Acta Oncol, vol.33, issue.6, pp.591-599, 1994.

P. Wiernik, X. Hu, and H. Ratech, Non-Hodgkin's lymphoma in women with breast cancer

, Cancer J, 2000.

. Sep-oct, , vol.6, pp.336-378

M. Dollinger, Guidelines for Hospitalization for Chemotherapy, Oncologist, vol.1, issue.1, pp.107-111, 1996.

C. Laurent, M. Baron, A. N. Haioun, C. Dandoit, M. Maynadié et al., Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network, J Clin Oncol, vol.35, issue.18, pp.2008-2017, 2017.

J. C. Jozette, R. P. Stienen, and . Hermens, Lianne Wennekes et al. Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics, BMC Cancer, vol.15, p.578, 2015.

C. Guglielmi, F. Gomez, T. Philip, A. Hagenbeek, M. Martelli et al., Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial, J Clin Oncol, vol.16, pp.3264-3273, 1998.

C. Casulo, M. Byrtek, K. L. Dawson, X. Zhou, C. M. Farber et al., Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study, J Clin Oncol, vol.33, issue.23, pp.2516-2538, 2015.

S. H. Bachow, O. Connor, and O. A. , Emerging therapies in relapsed and refractory peripheral T-cell lymphoma, Clin Adv Hematol Oncol, vol.13, issue.12, pp.837-883, 2015.

F. Montanari and C. Diefenbach, Relapsed Hodgkin lymphoma: management strategies, Curr Hematol Malig Rep, vol.9, issue.3, pp.284-93, 2014.

S. Romio, M. Sturkenboom, and G. Corrao, Real-world data from the health decision maker perspective. What are we talking about?, Epidemiology Biostatistics and Public Health -2013, vol.10, issue.3, p.115

C. Rioufol, S. Lamy, C. Conte, P. Jeanneau, G. Compaci et al., Non-cancer drug consumption during the early trajectory of lymphoma survivorship. Thérapie, Annexes, vol.3, issue.17, pp.30186-30191, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01907809

G. Lapeyre-mestre, C. Laurent, F. Rioufoll, . Despas-;-pauline, G. Jeanneau et al., Funding acquisition: Guy Laurent. Methodology: Maryse Lapeyre-Mestre, Guy Laurent, Catherine Rioufoll, Fabien Despas, Cyrille Delpierre. Resources: Maryse Lapeyre-Mestre, Fabien Despas, Guy Laurent. Software: Catherine Rioufoll, Sébastien Lamy, Cyrille Delpierre, Cécile conte. Supervision: Maryse Lapeyre-Mestre, Fabien Despas, Guy Laurent. Validation: All authors. Writing -original draft: Catherine Rioufoll, Conceptualization: Maryse

N. F. Khan, A. M. Ward, E. Watson, and P. W. Rose, Consulting and prescribing behaviour for anxiety and depression in long-term survivors of cancer in the UK, Eur J Cancer, vol.46, issue.18, pp.3339-3383, 2010.

M. Heins, F. Schellevis, M. Rijken, L. Van-der-hoek, and J. Korevaar, Determinants of increased primary health care use in cancer survivors, J Clin Oncol, vol.30, issue.33, pp.4155-60, 2012.

G. Compaci, M. Rueter, S. Lamy, L. Oberic, C. Recher et al., Ambulatory medical assistance-after cancer (AMA-AC): a model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy, BMC Cancer, vol.15, p.781, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01912614

B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht et al., Revised response criteria for malignant lymphoma, J Clin Oncol, vol.25, issue.5, pp.579-86, 2007.

W. Index, , 2016.

S. C. Montamat and B. Cusack, Overcoming problems with polypharmacy and drug misuse in the elderly, Clin Geriatr Med, vol.8, issue.1, pp.143-58, 1992.

E. R. Hajjar, A. C. Cafiero, and J. T. Hanlon, Polypharmacy in elderly patients, Am J Geriatr Pharmacother, vol.5, issue.4, pp.345-51, 2007.

D. Razavi, N. Delvaux, C. Farvacques, and E. Robaye, Validation de la version française du HADS dans une population de patients cancéreux hospitalisés, Rev Psychol Appliquee, vol.39, issue.4, pp.295-307, 1989.

A. S. Zigmond and R. P. Snaith, The hospital anxiety and depression scale, Acta Psychiatr Scand, vol.67, issue.6, pp.361-70, 1983.

L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill et al., The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, Blood, vol.109, issue.5, pp.1857-61, 2007.

P. Solal-céligny, P. Roy, P. Colombat, J. White, J. O. Armitage et al., Follicular lymphoma international prognostic index, Blood, vol.104, issue.5, pp.1258-65, 2004.

D. Hasenclever and V. Diehl, A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease, N Engl J Med, vol.339, issue.21, pp.1506-1520, 1998.

O. Boeuf-cazou, M. Lapeyre-mestre, M. Niezborala, and J. L. Montastruc, Evolution of drug consumption in a sample of French workers since 1986: the 'Drugs and Work' study, Pharmacoepidemiol Drug Saf, vol.18, issue.4, pp.335-378, 2009.

E. D. Kantor, C. D. Rehm, J. S. Haas, A. T. Chan, and E. L. Giovannucci, Trends in prescription drug use among adults in the United States from 1999-2012, JAMA, vol.314, issue.17, pp.1818-1849, 2015.

E. Yucel, M. Sancar, A. Yucel, and B. Okuyan, Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method, Expert Opin Drug Saf, vol.15, issue.2, pp.223-259, 2016.

J. W. Kim, K. L. Lee, J. B. Jeong, B. G. Kim, S. Shin et al., Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea, World J Gastroenterol, vol.16, issue.28, pp.3573-3580, 2010.

S. Dublin, R. L. Walker, M. L. Jackson, J. C. Nelson, N. S. Weiss et al., Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study, Pharmacoepidemiol Drug Saf, vol.19, issue.8, pp.792-802, 2010.

D. A. Corley, A. Kubo, W. Zhao, and C. Quesenberry, Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients, Gastroenterology, vol.139, issue.1, pp.93-101, 2010.

F. Desplenter, C. Bond, M. Watson, C. Burton, P. Murchie et al., Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study

, Br J Cancer, vol.107, pp.1644-51, 2012.

C. G. Ng, M. Boks, H. M. Smeets, and Z. Niek, Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands, Psychooncology, vol.22, pp.762-769, 2013.

C. Conte, M. Rueter, G. Laurent, R. Bourrel, M. Lapeyre-mestre et al., Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database, Support Care Cancer, vol.24, issue.11, pp.4791-4800, 2016.

S. K. Smith, S. Zimmerman, C. S. Williams, J. S. Preisser, and E. C. Clipp, Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors, J Clin Oncol, vol.26, issue.6, pp.934-975, 2008.

S. Singer, J. Das-munshi, and E. Brähler, Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis

, Ann Oncol, vol.21, issue.5, pp.925-955, 2010.

A. J. Mitchell, M. Chan, H. Bhatti, M. Halton, L. Grassi et al., Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological

C. Rioufol, Non-cancer drug consumption during the early trajectory of lymphoma survivorship, Therapie, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01907809

, ARTICLE IN PRESS +Model THERAP, vol.216, p.11

, Non-cancer drug in lymphoma survivors 11 settings: a meta-analysis of 94 interview-based studies, Lancet Oncol, vol.12, issue.2, pp.160-74, 2011.

J. Alonso, M. C. Angermeyer, S. Bernert, R. Bruffaerts, T. S. Brugha et al., Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project, Acta Psychiatr Scand Suppl, vol.420, pp.55-64, 2004.

I. M. Braun, S. R. Rao, F. L. Meyer, and G. Fedele, Patterns of psychiatric medication use among nationally representative long-term cancer survivors and controls, Cancer, vol.121, issue.1, pp.132-140, 2015.